Menu

Women Lose Vision After Stem Cell Treatment

The adipose-derived cells were injected into the patients’ eyes to treat age-related macular degeneration. 

Mar 17, 2017
Kerry Grens

WIKIPEDIA, TMHLEEThree women were blinded following a procedure involving the injection of adipose-derived stem cells into their eyes, according to a report in the New England Journal of Medicine today (March 16). The patients were looking for a treatment to abate age-related macular degeneration, but within days of the experimental therapy they suffered severe complications.

Such stem cell treatments—when taken from the patients’ own bodies—are largely unregulated by the US Food and Drug Administration, and also largely unproven. “There is little question that when the FDA is involved in regulatory oversight, it works in favor of patient safety,” Stanford University’s Jeffrey Goldberg, a coauthor of the paper, told STAT News. “That would have protected patients in cases like these.”

According to Kaiser Health News, a Florida-based company formerly known as Bioheart Inc. and now called U.S. Stem Cell, sponsored the experimental treatment, which the firm had listed on clinicaltrials.gov, featuring the stem-cell procedure. But there were serious flaws, according to Goldberg’s report, including a lack of safety data.

“Is this just the tip of the iceberg for negative stem cell clinic outcomes given that there are around 600 such clinics in the US today largely operating generally without FDA approvals, lacking preclinical data to support what they are doing, and experimenting on thousands of patients for profit?” Paul Knoepfler, a stem cell biologist at the University of California, Davis, School of Medicine, wrote in a blog post.

Another group of researchers concurrently reported in the New England Journal of Medicine having success implanting a sheet of retinal pigment epithelial cells, derived from induced pluripotent stem (iPS) cells, to treat macular degeneration in an elderly woman. Following treatment, the patient’s vision didn’t not worsen a year after treatment.

This experiment, in contrast to the one in Florida, was lauded as “a landmark” by Harvard Medical School’s George Daley, who spoke with NPR. “It’s the first time any patient has been treated with cellular derivatives of iPS cells. So it’s definitely a world first,” said Daley, who was not part of the study. (Researchers have also had some success implanting human embryonic stem cells to treat macular degeneration.)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.